I. Expression across cell types
Name | Number of supported studies  | Average coverage | |
|---|---|---|---|
| mesothelial cell | 12 studies | 65% ± 22% | |
| type I pneumocyte | 7 studies | 56% ± 20% | |
| endothelial cell | 4 studies | 54% ± 7% |
Name | Number of supported studies | Average coverage | |
|---|---|---|---|
| mesothelial cell | 12 studies | 65% ± 22% | |
| type I pneumocyte | 7 studies | 56% ± 20% | |
| endothelial cell | 4 studies | 54% ± 7% |
Name | Number of supported studies | Average coverage | |
|---|---|---|---|
| brain | 3 studies | 37% ± 21% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
|---|---|---|---|---|---|---|
| ovary | 69% | 485.38 | 125 / 180 | 97% | 194.05 | 417 / 430 |
| bladder | 86% | 2191.19 | 18 / 21 | 63% | 175.16 | 315 / 504 |
| lung | 99% | 3206.32 | 575 / 578 | 48% | 15.83 | 559 / 1155 |
| esophagus | 52% | 1233.28 | 748 / 1445 | 53% | 11.75 | 97 / 183 |
| uterus | 49% | 104.59 | 83 / 170 | 52% | 35.62 | 238 / 459 |
| ureter | 0% | 0 | 0 / 0 | 100% | 11.20 | 1 / 1 |
| prostate | 80% | 189.53 | 196 / 245 | 2% | 0.20 | 11 / 502 |
| spleen | 80% | 153.14 | 193 / 241 | 0% | 0 | 0 / 0 |
| thymus | 73% | 108.73 | 476 / 653 | 3% | 0.43 | 19 / 605 |
| breast | 66% | 117.50 | 301 / 459 | 6% | 0.80 | 71 / 1118 |
| skin | 71% | 240.74 | 1283 / 1809 | 0% | 0.04 | 2 / 472 |
| adipose | 70% | 3439.28 | 846 / 1204 | 0% | 0 | 0 / 0 |
| stomach | 53% | 144.28 | 192 / 359 | 16% | 3.41 | 45 / 286 |
| pancreas | 20% | 25.41 | 66 / 328 | 46% | 24.56 | 82 / 178 |
| tonsil | 0% | 0 | 0 / 0 | 56% | 15.04 | 25 / 45 |
| intestine | 38% | 57.90 | 366 / 966 | 14% | 5.91 | 72 / 527 |
| peripheral blood | 40% | 149.13 | 372 / 929 | 0% | 0 | 0 / 0 |
| heart | 21% | 279.53 | 178 / 861 | 0% | 0 | 0 / 0 |
| adrenal gland | 20% | 24.09 | 51 / 258 | 1% | 0.05 | 2 / 230 |
| kidney | 16% | 18.00 | 14 / 89 | 4% | 1.05 | 35 / 901 |
| liver | 12% | 12.81 | 27 / 226 | 4% | 1.34 | 17 / 406 |
| blood vessel | 13% | 75.76 | 172 / 1335 | 0% | 0 | 0 / 0 |
| brain | 7% | 7.19 | 195 / 2642 | 0% | 0.03 | 3 / 705 |
| muscle | 3% | 3.31 | 24 / 803 | 0% | 0 | 0 / 0 |
| eye | 0% | 0 | 0 / 0 | 3% | 0.18 | 2 / 80 |
| abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| lymph node | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 29 |
| nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| GO_0010629 | Biological process | negative regulation of gene expression |
| GO_0016020 | Cellular component | membrane |
| GO_0005886 | Cellular component | plasma membrane |
| Gene name | UPK3B |
| Protein name | Uroplakin-3b (UP3b) (Uroplakin IIIb) (UPIIIb) (p35) Uroplakin-3b |
| Synonyms | |
| Description | FUNCTION: Component of the asymmetric unit membrane (AUM); a highly specialized biomembrane elaborated by terminally differentiated urothelial cells. May play an important role in AUM-cytoskeleton interaction in terminally differentiated urothelial cells. It also contributes to the formation of urothelial glycocalyx which may play an important role in preventing bacterial adherence (By similarity). . |
| Accessions | ENST00000631529.1 ENST00000615976.2 ENST00000448265.7 ENST00000334348.8 [Q9BT76-3] A0A0J9YVS6 ENST00000257632.9 [Q9BT76-1] Q9BT76 ENST00000394849.1 [Q9BT76-2] |
